TherapeuticsMD (TXMD) Short-term Investments (2022)

TherapeuticsMD (TXMD) posted Short-term Investments of $11.2 million for Q4 2022, little changed on a QoQ basis from $11.2 million in Q3 2022.

TherapeuticsMD (TXMD) Short-term Investments (2022) Analysis & Trends

TherapeuticsMD's Short-term Investments history runs 1 years deep, the most recent figure standing at $11.2 million for Q4 2022.

  • Quarterly Short-term Investments changed N/A year-over-year to $11.2 million in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $11.2 million (changed N/A YoY) and the FY2022 annual result came in at $11.2 million, changed N/A from the prior year.
  • Short-term Investments was $11.2 million for Q4 2022 at TherapeuticsMD, roughly flat from $11.2 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $11.2 million in Q2 2022 and bottomed at $11.2 million in Q2 2022.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Haleon 87.22 Bn 85.35 Bn -
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn
10 TherapeuticsMD 280,159.99 -8.14 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2022 11.25 Mn
Sep 30, 2022 11.25 Mn
Jun 30, 2022 11.25 Mn